Shire Preparing For All Potential Outcomes As It Awaits Lifitegrast Approval Decision
This article was originally published in The Pink Sheet Daily
Executive Summary
The specialty firm hopes for a first-cycle approval of the dry eye candidate by the action date of Oct. 25, but is conducting an additional Phase III trial in case further symptom-relief efficacy data are needed.